Clinical Trial: Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904338) titled 'Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN' on Oct. 23.

Brief Summary: This is a prospective, multicenter, non-interventional, observational pharmacological real-world study to characterize longitudinal changes in ex vivo biomarkers of complement activation in patients with C3G and primary IC-MPGN receiving pegcetacoplan in routine clinical practice.

The study will involving fifteen adult and adolescent patients who will undergo serial collection of biological samples for ex vivo assess...